問卷

TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Infectious Disease

更新時間:2023-09-19

林蔚如
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

14Cases

2008-01-01 - 2010-10-31

Others

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2015-10-01 - 2017-07-31

Phase I/II

Completed
A Phase I-II Study of the Safety and Efficacy of a True Human Antibody, 514G3, in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus
  • Condition/Disease

    Staphylococcus Aureus bacteremia

  • Test Drug

    514G3

Participate Sites
6Sites

Terminated4Sites

2007-12-25 - 2009-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2005-12-01 - 2007-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Study ended10Sites

2014-02-07 - 2015-07-30

Phase II/III

A Phase 3, multicenter, randomized, double-blind, active controlled study to evaluate the efficacy and safety of IV and oral delafloxacin compared with vancomycin + aztreonam in patients with acute bacterial skin and skin structure infections
  • Condition/Disease

    acute bacterial skin and skin structure infections

  • Test Drug

    Delafloxacin

Participate Sites
7Sites

Terminated7Sites

2011-11-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2015-01-02 - 2016-06-30

Phase III

A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy Study to Evaluate the Efficacy, Safety, and Tolerability of Carbavance (Meropenem/RPX7009) Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, in Adults
  • Condition/Disease

    Complicated Urinary Tract Infections, Including Acute Pyelonephritis, in Adults

  • Test Drug

    Carbavance(meropenem/RPX7009)

Participate Sites
4Sites

Terminated4Sites

2012-02-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

1 2